Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Somatic mutations in IDH genes are seen in ∼20% of patients with AML, with mutations in IDH2 (R172, R140) being more common (15%) than IDH1 (R132). We previously reported a higher 1-year relapse rate after HCT in patients with IDH mutations (mIDH; PMC9129101). We hypothesized that enasidenib, an IDH2 inhibitor, is well-tolerated as post-HC T maintenance, and can improve leukemia free survival (LFS) in AML patients carrying mIDH2. Here, we are reporting the final results of our completed multicenter [City of Hope (COH) and Moffitt Cancer Center] pilot trial (NCT03728335), previously reported in 2022 ASH meeting with a shorter follow-up period.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Amandeep Salhotra, Nelli Bejanyan, Dongyun Yang, Sally Mokhtari, Monzr M. Al Malki, Karamjeet S. Sandhu, Rawan G Faramand, Ibrahim Aldoss, Andrew S. Artz, Ahmed Aribi, Hany Elmariah, Firoozeh Sahebi, Joshua Mansour, Brian Ball, Vaibhav Agrawal, Ling Li, V Tags: 10 Source Type: research